Cargando…
Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836292/ https://www.ncbi.nlm.nih.gov/pubmed/33521304 http://dx.doi.org/10.1016/j.medcle.2020.07.009 |
| _version_ | 1783642716954951680 |
|---|---|
| author | Jiménez-Brítez, Gustavo Ruiz, Pablo Soler, Xavier |
| author_facet | Jiménez-Brítez, Gustavo Ruiz, Pablo Soler, Xavier |
| author_sort | Jiménez-Brítez, Gustavo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7836292 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier España, S.L.U. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78362922021-01-26 Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience Jiménez-Brítez, Gustavo Ruiz, Pablo Soler, Xavier Med Clin (Engl Ed) Scientific Letter Elsevier España, S.L.U. 2020-11-13 2020-11-09 /pmc/articles/PMC7836292/ /pubmed/33521304 http://dx.doi.org/10.1016/j.medcle.2020.07.009 Text en © 2020 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Scientific Letter Jiménez-Brítez, Gustavo Ruiz, Pablo Soler, Xavier Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title | Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title_full | Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title_fullStr | Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title_full_unstemmed | Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title_short | Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience |
| title_sort | tocilizumab plus glucocorticoids in severe and critically covid-19 patients. a single center experience |
| topic | Scientific Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836292/ https://www.ncbi.nlm.nih.gov/pubmed/33521304 http://dx.doi.org/10.1016/j.medcle.2020.07.009 |
| work_keys_str_mv | AT jimenezbritezgustavo tocilizumabplusglucocorticoidsinsevereandcriticallycovid19patientsasinglecenterexperience AT ruizpablo tocilizumabplusglucocorticoidsinsevereandcriticallycovid19patientsasinglecenterexperience AT solerxavier tocilizumabplusglucocorticoidsinsevereandcriticallycovid19patientsasinglecenterexperience |